Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?
about
Platinum versus non-platinum chemotherapy regimens for small cell lung cancerOrigins, genetic landscape, and emerging therapies of small cell lung cancerStaging and imaging of small cell lung cancerTherapeutic procedure in small cell lung cancerUsing administrative health data to describe colorectal and lung cancer care in New South Wales, Australia: a validation study.A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010.Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.Nomogram prediction for the survival of the patients with small cell lung cancer.Progression-free survival: an important prognostic marker for long-term survival of small cell lung cancerTemporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients.Do multidisciplinary meetings follow guideline-based care?Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancerClinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancerMultidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinomaElevated serum C-reactive protein as a prognostic marker in small cell lung cancerc-kit expression in adenocarcinomas of the lung.Neuroendocrine carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 14 casesChemoradiotherapy for lung cancer.The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung CancerSurvival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the question.Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer.Management of small-cell lung cancer with radiotherapy-a pan-Canadian survey of radiation oncologists.The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer.Current concepts in the management of small cell lung cancer.A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancerExtrapulmonary small cell carcinoma localized in lymph nodes: is it a different clinical entity?Radiochemotherapy in small-cell lung cancer.Progress in the management of limited-stage small cell lung cancer.MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.Primary small-cell carcinoma of the breast.High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease.Prophylactic cranial irradiation for small-cell lung cancer: how, when and for whom?Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting.The role of radiation therapy in small cell lung cancer.Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?Recent developments in radiotherapy for small-cell lung cancer: a review by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer.Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
P2860
Q24188039-9EBC7549-572D-4074-89A9-6EEDA63D321BQ26798218-47C67674-D0B2-4C55-AE5B-E2A03ECEC8B0Q26852956-5024FFEC-F167-4150-871D-EB10B1CC247BQ26861330-780B5027-A3EB-4E48-93F8-B0075991935BQ30576997-72E9CD00-0EC6-499F-AA43-F44242BDB044Q30633067-43A058D4-BE60-44BD-8BF9-8FEA7585C4B0Q33394192-B028DBA8-B691-4C67-8A2C-A762388F6406Q33571276-787F18EB-A7E1-4165-891C-F0AA9D6190A4Q33728681-2EF77DEE-211E-4E58-AFE5-13C1868777EFQ34226656-A7AB1100-1518-47FF-9E14-AE2EF80EBB8FQ34335054-78323482-5D93-4CE3-813F-7420996D2B65Q34419020-861CF3F8-E30A-4453-B9DA-881B65B7D645Q34502009-DCDC3F2E-2B41-4DAF-A372-A9CF06161ACEQ34853559-0CE41737-795E-483E-A3CD-071C133B9BCBQ35648199-8B12BF10-6CA6-48B9-A9B1-B5B1A7F93E76Q35997750-F0AA526B-DDEC-4EBE-BEFA-2208B62084CBQ36306218-AA7707F5-EC4B-46A5-8878-F1FBF4E8A519Q36327084-E7372EFD-E091-4465-9BBC-E3E0D24B9C48Q36567055-E12179AB-81E4-4F9B-9B51-2AAC974AEAD3Q36776647-241B4875-14B4-4670-8EFC-D59338F7AB94Q36874800-4AB981D8-8D25-4BE1-AB70-6548A1053D37Q36947998-8554DDD5-1FB3-44BE-9105-29F76A9AF09CQ36989079-26AE045E-D5F5-44B0-8956-C492D6822ECDQ37015297-A3E0A30B-B49F-4F73-845D-F82F53D01D1DQ37073202-6C929694-4C52-4785-B3FD-EE1EDC2F412CQ37118188-1C7FBDE3-E40C-473A-A441-A73BB9D232FDQ37225619-01F7BF65-6A04-4EA2-91E3-78787E4D71AAQ37315618-068778F0-6D10-43D2-918B-5ADEF758672DQ37614569-E3D64C0C-4ECD-4FEE-B0E5-BD7F2E5027EDQ37626969-5F32A46F-A81C-4BBA-AB49-3B12E6EBFCD1Q37661175-3449D6B1-EB72-470E-9077-277B69BB5D26Q37699067-F6B9E82B-6A81-4BA8-9BDF-E1EA9AC60B58Q37788615-CCE1C6A4-C0F9-4376-8335-E266CA60E404Q38002472-25B50F81-2112-4941-B0FA-C6B68BC83CFBQ38039073-5BA1D892-07C2-4CC8-8783-3D810A6EEE84Q38102613-CAC71D7A-B57A-4B6F-9B85-869F43DE7374Q38323055-35DE615F-E12A-4A65-AC61-3299DE5E0DE3Q38690406-BA2DB65C-EE25-45C0-998C-AFEB19F075E5Q38919028-E6297DD4-9758-4DDA-B323-6747C932641AQ38996164-C9EE66EE-34AF-4C1C-9ACE-0296B80CE3D9
P2860
Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Staging small cell lung cancer ...... --what limits limited disease?
@en
type
label
Staging small cell lung cancer ...... --what limits limited disease?
@en
prefLabel
Staging small cell lung cancer ...... --what limits limited disease?
@en
P2093
P1433
P1476
Staging small cell lung cancer ...... --what limits limited disease?
@en
P2093
Andreas Faldum
Fernando Bittinger
Kai-Michael Beeh
Patrick Micke
Roland Buhl
Tsegay Metz
P304
P356
10.1016/S0169-5002(02)00072-7
P577
2002-09-01T00:00:00Z